Skip to main content
[Preprint]. 2023 Oct 18:2023.10.15.562398. [Version 1] doi: 10.1101/2023.10.15.562398

Table 4:

Six hits from SIDER with the structural alerts for the DICT most-concern category.

Compounds Name Compound Structure Structural Alert Present Status in DrugBank Comment based on Literature
Delavirdine graphic file with name nihpp-2023.10.15.562398v1-t0007.jpg graphic file with name nihpp-2023.10.15.562398v1-t0008.jpg Approved
Ipratropium graphic file with name nihpp-2023.10.15.562398v1-t0009.jpg graphic file with name nihpp-2023.10.15.562398v1-t0010.jpg Approved, Experimental Use of ipratropium bromide within the past 6 months is associated with an increased risk of cardiovascular events.79
Butylscopolamine graphic file with name nihpp-2023.10.15.562398v1-t0011.jpg graphic file with name nihpp-2023.10.15.562398v1-t0012.jpg Approved, Investigational
Dabigatran graphic file with name nihpp-2023.10.15.562398v1-t0013.jpg graphic file with name nihpp-2023.10.15.562398v1-t0014.jpg Approved, Investigational Dabigatran effectively treats various cardiovascular diseases, with emerging studies assessing its use in malignancy associated VTE and other conditions.82
Tiotropium graphic file with name nihpp-2023.10.15.562398v1-t0015.jpg graphic file with name nihpp-2023.10.15.562398v1-t0016.jpg Approved Tiotropium may increase the risk of coronary heart disease in patients over 55, especially high-exposure users.80
Mivacurium graphic file with name nihpp-2023.10.15.562398v1-t0017.jpg graphic file with name nihpp-2023.10.15.562398v1-t0018.jpg Approved Mivacurium chloride affects blood pressure and heart rate varying with dosage while rapid injections lead to pronounced changes.81